FundComb

Investment and M&A transaction comps

Healthcare Investment & M&A Transaction Comps

Healthcare services, healthcare IT, medtech, diagnostics, life sciences tools and related healthcare transactions. Pure biotech rows are tracked separately where normal revenue multiples are less meaningful.

Consumer CPG Beauty Supplements Food & Beverage Healthcare
18
Reviewed transactions
6
With price data
4.8x
Median EV or valuation / revenue
11.0x
Median EV or valuation / EBITDA
Year Transactions Priced Median EV or valuation / revenue Median EV or valuation / EBITDA
2026 6 1 - -

Sortable transaction comps

Healthcare transaction table

Filter transactions

Narrow the table without crowding the main view.

Clear all filters

Rows with reported value

1 / 2

Acquisition EV, USD

USD 1.6B

Investment EV, USD

-

Median EV / revenue

6.0x

Columns

Show columns

Select up to 12 rows across filters and pages, then share or export the set.

2 shown of 2 matching transactions. Click any transaction row for more detail.

Values are 100% enterprise values. Multiples divide EV by full-company revenue or EBITDA. Reported prices are assumed to be EV; explicit partial-stake prices are grossed up as estimates. Amounts paid are tracked separately.

Select for comparison
Tubulis
Control
 2026-05-21 Gilead Sciences Undisclosed - -
BiotechAntibody Drug Conjugates
+2
OncologyTherapeutics
- Telix Pharmaceuticals Limited 1,650 6.0x -
BiotechDrug Development
+2
Radioisotope ManufacturingRadiopharmaceuticals
FundComb transaction comps are informational only. Prices are shown as estimated enterprise value where available, with USD used as the default sorting currency; revenue and EBITDA multiples are shown where available. Values may be estimated, rumored, incomplete or derived from public information and should not be relied upon as financial, investment or valuation advice.